Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significantly poorer » significantly shorter (Expand Search), significantly lower (Expand Search), significantly longer (Expand Search)
poorer decrease » scores decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significantly poorer » significantly shorter (Expand Search), significantly lower (Expand Search), significantly longer (Expand Search)
poorer decrease » scores decreased (Expand Search)
-
1901
-
1902
-
1903
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
1904
-
1905
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
1906
-
1907
-
1908
-
1909
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
1910
-
1911
-
1912
-
1913
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
1914
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
1915
-
1916
-
1917
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
1918
-
1919
-
1920